Type 1 Diabetes Starts at Birth
Type 1 diabetes cases rise worldwide but early triggers stay unclear. Population studies rarely catch signals before islet autoimmunity begins. Pediatric endocrinologists need markers present at birth. This Swedish study finds them through proteomics. The results were published in the Nature Communications. 
Massive Birth Cohort Yields Clues
Researchers analyzed the ABIS birth cohort of 16,683 Swedish children. Olink proteomics measured inflammatory proteins in 286 controls and 146 T1D cases at birth. Diagnosis came at mean age 12.6 years later. Proteins showed differences years before symptoms appeared.
Neutrophils and Matrix Mark Risk
Birth samples revealed higher neutrophil migration and cytotoxicity proteins in future T1D cases. Extracellular matrix remodeling signals appeared elevated too. Immune regulation proteins changed early. Markers stayed significant despite family diabetes history.
Metabolites and Toxins Tie In
High-risk protein patterns linked to altered stearic acid, lysine, and glutamine levels. Persistent toxins like perfluorodecylethanoic acid and PFOS associated with the signature. Environment meets biology at birth.
Machine Learning Nails Prediction
Protein subset predicted T1D with area under curve 0.89 plus or minus 0.02 using machine learning. Prediction worked independent of HLA genetic risk. Accuracy held across the cohort.
Prevention Window Opens Early
β-cell stress and innate immune shifts happen before adaptive autoimmunity. Non-invasive birth screening could identify at-risk infants. Lifestyle or immune modulation might protect islets proactively.
Screen Newborns for Diabetes Risk
Neonatologists should consider proteomics panels at birth. Early surveillance beats late intervention. Findings demand replication in other populations now.